A team of highly experienced industry experts

Azafaros is supported by a syndicate of leading Dutch and Swiss investors. Our clinical candidate, nizubaglustat, is an orally available azasugar designed to treat the central nervous system and to interfere with the metabolism of glycosphingolipids affecting key disease pathways through a unique dual mode of action.

Read more about Azafaros